Jithma P Abeykoon
Overview
Explore the profile of Jithma P Abeykoon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
513
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paludo J, Abeykoon J, Perera N, Sarosiek S, Gustine J, Ramirez-Gamero A, et al.
Am J Hematol
. 2025 Mar;
PMID: 40062689
As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However,...
2.
Acosta-Medina A, Abeykoon J, Zanwar S, Ruan G, Rech K, Ravindran A, et al.
Leukemia
. 2025 Feb;
PMID: 39934281
No abstract available.
3.
Erdheim-Chester Disease With Significant Response of Large Vessel Disease to Cobimetinib Monotherapy
Ahmed N, Abeykoon J, Collie A, Koster M
Am J Hematol
. 2025 Jan;
PMID: 39840501
No abstract available.
4.
Makras P, Erickson D, Davidge-Pitts C, Diamond E, Allen C, McClain K, et al.
J Clin Endocrinol Metab
. 2024 Dec;
PMID: 39699236
Endocrinopathies are frequently the initial presentation of histiocytic neoplasms, which are rare hematologic disorders affecting multiple organ systems. Langerhans cell histiocytosis and Erdheim-Chester disease are 2 such disorders known to...
5.
Smith K, Acosta-Medina A, Dasari S, Ranatunga W, Rech K, Ravindran A, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400471.
PMID: 39576953
Purpose: BRAF and MEK inhibitors are standard treatments in histiocytic disorders, such as Erdheim-Chester disease (ECD). Some patients lack MAPK-pathway alterations, making these treatments less effective. Methods: We describe three...
6.
Abeykoon J, Go R, Azoulay L, Haroche J
Br J Haematol
. 2024 Nov;
206(2):792-794.
PMID: 39535303
Lin et al. report the long-term follow-up of a phase II trial involving 95 adult patients with Langerhans cell histiocytosis (LCH), investigating the combination of methotrexate and cytarabine (MA). After...
7.
Nathoo N, Larson D, Guo Y, Giannini C, Lucchinetti C, Micallef I, et al.
Eur J Neurol
. 2024 Oct;
32(1):e16528.
PMID: 39460456
Background: Crystal-storing histiocytosis (CSH) is a rare form of histiocytosis with intralysosomal accumulations of immunoglobulins or paraproteins that aggregate as crystals. Central nervous system (CNS) involvement of CSH is uncommon...
8.
Banks S, Abeykoon J, Rech K, Morris P, Tan Q, Veres L, et al.
Neurol Genet
. 2024 Oct;
10(6):e200197.
PMID: 39421731
Objectives: Pathogenic variants are known to cause autosomal recessive disease with a spectrum of systemic involvement. We sought to expand on the spectrum of variants and describe potential treatment. Methods:...
9.
Gile J, Maurer M, Ruan G, Abeykoon J, Heimgartner J, Baumann N, et al.
Oncologist
. 2024 Oct;
29(12):e1779-e1782.
PMID: 39418117
Magnesium (Mg) is an essential element involved in cellular metabolism. We demonstrated that in patients with diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (SCT), those with a...
10.
Banks S, Decker P, Flanagan E, Zekeridou A, Go R, Abeykoon J, et al.
Blood Cancer J
. 2024 Sep;
14(1):153.
PMID: 39237493
No abstract available.